Results 1 to 10 of about 15,200 (191)

Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma [PDF]

Frontiers in Oncology, 2022
BackgroundThe anti-CD38 monoclonal antibody daratumumab is the backbone of most anti-multiple myeloma (MM) regimens. To mitigate the risk of infusion-related reactions (IRRs), intravenous daratumumab administration requires 7 hours for the first infusion
Francesca Bonello, Serena Rocchi, Serena Rocchi, Gregorio Barilà, Michela Sandrone, Marco Talarico, Marco Talarico, Elena Zamagni, Elena Zamagni, Matilde Scaldaferri, Susanna Vedovato, Cecilia Bertiond, Laura Pavan, Sara Bringhen, Francesco Cattel, Renato Zambello, Michele Cavo, Michele Cavo, Roberto Mina   +18 more
doaj   +6 more sources

Daratumumab‐Based Combinational Therapy as Second‐Line Treatment of Relapsed‐Refractory Multiple Myeloma: A Single‐Center Experience [PDF]

Cancer Reports
Background Daratumumab represents the first‐in‐class fully humanized monoclonal antibody that targets CD38 for the treatment of relapsed/refractory multiple myeloma (RRMM).
Oscar C. Y. Yang, Yi‐Hao Chiang, Caleb Gonshen Chen, Yu‐Cheng Chang, Ming‐Chih Chang, Huan‐Chau Lin, Johnson Lin, Ken‐Hong Lim   +7 more
doaj   +2 more sources

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis [PDF]

New England Journal of Medicine, 2021
Background Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells.
Efstathios Kastritis, Giovanni Palladini, Ashutosh D Wechalekar   +2 more
exaly   +3 more sources

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments

Frontiers in Oncology, 2021
Immunotherapy is changing the paradigm of multiple myeloma (MM) management and daratumumab is the first-in-class human monoclonal antibody targeting CD38 approved for the treatment of this malignancy. Daratumumab exerts anti-myeloma activity by different
Massimo Offidani, Laura Corvatta, Sonia Morè, Davide Nappi, Giovanni Martinelli, Attilio Olivieri, Claudio Cerchione   +6 more
doaj   +1 more source

Daratumumab [PDF]

Reactions Weekly, 2020
  +13 more sources

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma

HemaSphere, 2023
The CD38-targeting antibody daratumumab has marked activity in multiple myeloma (MM). Natural killer (NK) cells play an important role during daratumumab therapy by mediating antibody-dependent cellular cytotoxicity via their FcγRIII receptor (CD16), but
Christie P.M. Verkleij, Kristine A. Frerichs, Marloes E.C. Broekmans, Carolien Duetz, Chloe A. O’Neill, Wassilis S.C. Bruins, Paola M. Homan-Weert, Monique C. Minnema, Mark-David Levin, Annemiek Broijl, Gerard M.J. Bos, Marie José Kersten, Saskia K. Klein, Medya M. Shikhagaie, Tineke Casneuf, Yann Abraham, Tina Smets, Greet Vanhoof, Diana Cortes-Selva, Laure van Steenbergen, Elena Ramos, Raluca I. Verona, Maria Krevvata, Pieter Sonneveld, Sonja Zweegman, Tuna Mutis, Niels W.C.J. van de Donk   +26 more
doaj   +1 more source

Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers

Frontiers in Oncology, 2023
Daratumumab is a CD38-directed monoclonal antibody indicated to treat multiple myeloma (MM). Daratumumab was initially administered intravenously (IV), subsequently a subcutaneous (SC) formulation was developed to increase convenience of administration ...
Gordon Cook, John Ashcroft, John Ashcroft, Mariana Fernandez, Sarah Henshaw, Zeyad Khalaf, Guy Pratt, Anish Tailor, Neil Rabin   +8 more
doaj   +1 more source

CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy

Frontiers in Immunology, 2022
RationaleRecent studies have demonstrated the feasibility of CD38-specific antibody constructs for in vivo imaging of multiple myeloma. However, detecting multiple myeloma in daratumumab-pretreated patients remains difficult due to overlapping binding ...
Luca Julius Pape, Luca Julius Pape, Julia Hambach, Julia Hambach, Anna Josephine Gebhardt, Anna Josephine Gebhardt, Björn Rissiek, Tobias Stähler, Natalie Tode, Cerusch Khan, Cerusch Khan, Katja Weisel, Gerhard Adam, Friedrich Koch-Nolte, Peter Bannas   +14 more
doaj   +1 more source

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia [PDF]

, 2016
Increasing knowledge concerning the biology of hematologic malignancies as well as the role of the immune system in the control of these diseases has led to the development and approval of immunotherapies that are resulting in impressive clinical ...
Abonour, Rafat, Anderson, Kenneth C., Ansell, Stephen M., Avigan, David, Barbarotta, Lisa, Barrett, Austin John, Bergsagel, Leif, Bishop, Michael R., Borrello, Ivan, Boyiadzis, Michael, Brody, Joshua, Brufsky, Jill, Cairo, Mitchell, Chari, Ajai, Cohen, Adam, Cortes, Jorge, de Lima, Marcos, Dhodapkar, Madhav V., Forman, Stephen J., Friedberg, Jonathan W., Fuchs, Ephraim J., Gore, Steven D., Jagannath, Sundar, Kahl, Brad S, Kline, Justin, Kochenderfer, James N., Kwak, Larry W., Levy, Ronald, Litzow, Mark R., Mahindra, Anuj, Miller, Jeffrey, Munshi, Nikhil C., Orlowski, Robert Z., Pagel, John M., Porter, David L., Russell, Stephen J., Schwartz, Karl, Shipp, Margaret A., Siegel, David, Stone, Richard M., Tallman, Martin S., Timmerman, John M., Van Besien, Koen, Van Rhee, Frits, Waller, Edmund K., Welsh, Ann, Werner, Michael, Wiernik, Peter H.   +47 more
core   +5 more sources

Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)

Haematologica, 2020
Intravenous daratumumab is approved for the treatment of multiple myeloma. In Part 1 of the PAVO study, a mix-and-deliver subcutaneous formulation of daratumumab with recombinant human hyaluronidase PH20 (rHuPH20) was well tolerated, with low rates of ...
Jesus San-Miguel, Saad Z. Usmani, Maria-Victoria Mateos, Niels W.C.J. van de Donk, Jonathan L. Kaufman, Philippe Moreau, Albert Oriol, Torben Plesner, Lotfi Benboubker, Kevin Liu, Peter Hellemans, Tara Masterson, Pamela L. Clemens, Man Luo, Andrew Farnsworth, Hareth Nahi, Ajai Chari   +16 more
doaj   +1 more source